Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Paul Harker-Murray, MD PhD, Thierry Leblanc, MD, Maurizio Mascarin, Christine Mauz-Körholz, Gerard Michel, MD, Stacy Cooper, MD, Auke Beishuizen, MD PhD, Kasey J. Leger, MD MSc, Alberto Garaventa, Salvatore Buffardi, MD, Laurence Brugieres, MD, Kara M. Kelly, MD, Peter D. Cole, MD, Richard A. Drachtman, Faith Galderisi, DO, Mariana Sacchi, MD, Ying-Ming Jou, Stephen Daw

Blood (2018) 132 (Supplement 1): 927.

https://doi.org/10.1182/blood-2018-99-111279

Published: 2018

Journal Articles

Plasma Thymus and Activation-Regulated Chemokine (TARC) As Diagnostic Marker in Pediatric Hodgkin Lymphoma

Eline Zijtregtop, MD PhDcandidate, Waichu Wong, BSc, Friederike Meyer- Wentrup, MD PhD, Martha Lopez-Yurda, PhD, Raoull Hoogendijk, MSc, Patty Kok, BSc, Michel Zwaan, Prof., MD PhD, Auke Beishuizen, MD PhD

Blood (2018) 132 (Supplement 1): 5312.

https://doi.org/10.1182/blood-2018-99-111861

Published: 2018

Journal Articles

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Franco Locatelli, MD, Kathleen A Neville, MD, MS, Angelo Rosolen, MD, Judith Landman-Parker, MD, Nathalie Aladjidi, MD, Auke Beishuizen, MD, Stephen Daw, BSc Hons, MBChB, MRCP, Lia Gore, MD, Anna R.K. Franklin, MD, Adedigbo Fasanmade, PhD, Jingyuan Wang, PhD, Jessica Sachs, MD, Christine Mauz-Koerholz, MD

Blood (2013) 122 (21): 4378.

https://doi.org/10.1182/blood.V122.21.4378.4378

Published: 2013

Journal Articles

Endocrine Late Sequelae in Long-Term Survivors of Childhood Non-Hodgkin Lymphoma

Marjolein van Waas, MSc, Sebastian J.C.M.M. Neggers, MD, PhD, Mariel Lizet te Winkel, MD, Auke Beishuizen, MD, PhD, Rob Pieters, MD, PhD, Marry M. van den Heuvel-Eibrink, MD, PhD

Blood (2011) 118 (21): 5215.

https://doi.org/10.1182/blood.V118.21.5215.5215

Published: 2011

Journal Articles

T-Cell Receptor Vß CDR3 Oligoclonality Frequently Occurs in Childhood Refractory Cytopenia and Severe Aplastic Anemia.

Andrica C.H. de Vries, MD, Anton W. Langerak, MD, PhD, Brenda Verhaaf, Charlotte Marie Niemeyer, MD, PhD, Jan Stary, MD, PhD, Kjeld Schmiegelow, MD, PhD, Elisabeth van Wering, PhD, Auke Beishuizen, MD, PhD, Rob Pieters, MD, PhD, M.M. Van Den Heuvel, MD, PhD

Blood (2007) 110 (11): 2449.

https://doi.org/10.1182/blood.V110.11.2449.2449

Published: 2007

Journal Articles

A European Phase II Study (BIOV-111) of Clofarabine (Evoltra®) in Refractory and Relapsed Childhood Acute Lymphoblastic Leukemia: Final Results.

Pamela Kearns, MD, PhD, Gerard Michel, MD, Brigitte Nelken, MD, Simon Joel, PhD, Essam Al-Ghazaly, PhD, Auke Beishuizen, MD, PhD, Valentino Conter, MD, Gunter Henze, MD, Andre Baruchel, MD, Vaskar Saha, MD, PhD

Blood (2007) 110 (11): 11.

https://doi.org/10.1182/blood.V110.11.11.11

Published: 2007

Journal Articles

BIOV-111 a European Phase II Trial of Clofarabine (Evoltra ® ) in Refractory and Relapsed Childhood Acute Lymphoblastic Leukemia.

Pamela Kearns, MD,PhD, Gerard Michel, MD, Brigitte Nelken, MD, Simon Joel, PhD, Essam Al-Ghazaly, MD, Auke Beishuizen, MD,PhD, Valentino Conter, MD, Helmut Gadner, MD, Gunter Henze, MD, Hazel Smith, PhD, Andre Baruchel, MD, Vaskar Saha, MD, PhD

Blood (2006) 108 (11): 1859.

https://doi.org/10.1182/blood.V108.11.1859.1859

Published: 2006

Journal Articles

Anaplastic Large Cell Lymphoma (ALCL) in Children: Equal Efficacy but Greater Toxicity of Chemotherapy Including Methotrexate (MTX) 1g/m 2 in 24 Hour Infusion with Intra-Thecal Injection (IT) Than Chemotherapy with MTX 3g/m 2 in 3 Hours Infusion without IT: Results of the ALCL99-R1 Randomised Trial.

Laurence Brugières, MD, Marie Cécile Le Deley, MD, Angelo Rosolen, MD, Denise Williams, MD, Ke Horibe, MD, Grazyna Wrobel, MD, Anne Uyttebroeck, MD, Auke Beishuizen, MD, Georg Mann, MD, Karin Mellgren, MD, Alfred Reiter, MD

Blood (2006) 108 (11): 398.

https://doi.org/10.1182/blood.V108.11.398.398

Published: 2006

Journal Articles

Outcome of the Rotterdam-84 CNS-ALL Chemotherapy Protocol without Radiotherapy for Isolated Central Nervous System Relapsed Acute Lymphoblastic Leukemia.

Auke Beishuizen, MD, PhD, Femke K. Aarsen, MA, Jeanette E.W.M. van Dongen, PhD, MA, Isabelle C. Streng, MA, Rob Pieters, MD, PhD, Karel Hahlen, MD, PhD

Blood (2004) 104 (11): 1955.

https://doi.org/10.1182/blood.V104.11.1955.1955

Published: 2004

NARROW

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Plasma Thymus and Activation-Regulated Chemokine (TARC) As Diagnostic Marker in Pediatric Hodgkin Lymphoma

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Endocrine Late Sequelae in Long-Term Survivors of Childhood Non-Hodgkin Lymphoma

T-Cell Receptor Vß CDR3 Oligoclonality Frequently Occurs in Childhood Refractory Cytopenia and Severe Aplastic Anemia.

A European Phase II Study (BIOV-111) of Clofarabine (Evoltra®) in Refractory and Relapsed Childhood Acute Lymphoblastic Leukemia: Final Results.

BIOV-111 a European Phase II Trial of Clofarabine (Evoltra ® ) in Refractory and Relapsed Childhood Acute Lymphoblastic Leukemia.

Anaplastic Large Cell Lymphoma (ALCL) in Children: Equal Efficacy but Greater Toxicity of Chemotherapy Including Methotrexate (MTX) 1g/m 2 in 24 Hour Infusion with Intra-Thecal Injection (IT) Than Chemotherapy with MTX 3g/m 2 in 3 Hours Infusion without IT: Results of the ALCL99-R1 Randomised Trial.

Outcome of the Rotterdam-84 CNS-ALL Chemotherapy Protocol without Radiotherapy for Isolated Central Nervous System Relapsed Acute Lymphoblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only